RAC1 and nasopharyngeal carcinoma: This was confirmed to be only present in metastatic sites of oral carcinoma and sensitive to BEZ‐235 (dual PI3K/mTOR inhibitor) and trametinib (MEK1/2 inhibitor), as reported by Akiyama et al. 23 Finally, an RAC1 mutation (exon3: R68H) that was identified to be pathogenic in colon cancer24 was detected in one NPC case.